Neuroprognostication After Cardiac Arrest

 Neuroprognostication After Cardiac Arrest

A Grand Rounds Review for Postgraduate Trainees and Practicing Consultants

Dr Neeraj Manikath , claude.ai

Introduction: A Question That Haunts the ICU

A 58-year-old man is brought to your emergency department following a witnessed out-of-hospital cardiac arrest. Bystander CPR was initiated within two minutes; the rhythm was ventricular fibrillation, and return of spontaneous circulation (ROSC) was achieved after 22 minutes of resuscitation. He is intubated, haemodynamically stable on vasopressors, and transferred to the ICU for targeted temperature management (TTM). On day three, his pupils are sluggishly reactive, he withdraws to pain, and the EEG shows burst suppression. His wife, clutching his hand, asks you:

"Will he wake up? Will he be the same person I married?"

This scene replays thousands of times weekly in ICUs worldwide. Cardiac arrest survivors represent one of the most heterogeneous and prognostically challenging populations in all of acute medicine. Approximately 10–15% of out-of-hospital cardiac arrest patients survive to hospital discharge in high-income countries, yet among those who achieve ROSC, up to 70% will die or survive with severe neurological disability. The single most consequential decision a clinician makes in this setting is not which vasopressor to choose — it is whether, when, and how to prognosticate neurological outcome.

This review distils the current evidence into a practical, multimodal framework for neuroprognostication — one grounded in pathophysiology, sharpened by clinical pearls, and calibrated by hard-won bedside wisdom.

 

Pathophysiology: What You Need to Know to Prognosticate

Global cerebral ischaemia during cardiac arrest triggers a cascade of excitotoxicity, mitochondrial failure, and inflammatory injury that continues — and may worsen — after ROSC. This 'post-cardiac arrest brain injury' (PCABI) unfolds in temporally distinct phases, each with prognostic relevance.

Phase 1 (0–6 hours): Reperfusion injury dominates. Reactive oxygen species and glutamate-mediated excitotoxicity peak. Clinically, this window is unreliable for prognostication — even patients with seemingly intact neurological signs may deteriorate.

Phase 2 (6–72 hours): Delayed neuronal death, cerebral oedema, and apoptosis evolve. EEG abnormalities and elevated biomarkers (NSE, S100B) become diagnostically informative. TTM exerts its neuroprotective effect during this phase by attenuating inflammation and metabolic demand.

Phase 3 (>72 hours): Structural injury is largely fixed. This is the earliest reliable window for multimodal prognostication. The degree of cortical connectivity — reflected in SSEP responses, EEG reactivity, and biomarker trajectories — predicts functional recovery.

The key clinical take-away: any prognostic assessment performed before 72 hours after ROSC (or before 72 hours after TTM ends) risks both false pessimism and false optimism. Sedation, hypothermia, and ongoing organ dysfunction confound nearly every clinical sign in the early window.

 

🪙  CLINICAL PEARLS

Pearl 1: Absent pupillary reflexes are the most robust early sign — but interpret bilaterality strictly.

Bilateral absent pupillary light reflexes (PLR) at ≥72 h post-ROSC carry ~100% specificity for poor outcome. However, unilateral absence or sluggish responses are not sufficient for prognostication. Always examine both pupils, in a darkened room, with a bright light source. The quantitative pupillometer (NPi) reduces observer variability and identifies subtle responses invisible to the naked eye.

Pearl 2: Motor responses are unreliable after TTM.

Extension posturing (GCS motor = 2) was once considered a marker of poor prognosis. Post-TTM data shows that up to 15% of patients with good outcomes demonstrate extensor responses on day 3 — almost certainly a residual sedation effect. Never use motor response in isolation.

Pearl 3: Status myoclonus ≠ Lance-Adams syndrome.

Early (within 24–48 h) generalised myoclonus, especially if continuous and accompanied by a malignant EEG, predicts poor neurological outcome. This is distinct from Lance-Adams syndrome — action myoclonus emerging days-to-weeks later in a patient regaining consciousness — which is compatible with a good eventual outcome. Misclassifying these two entities causes both premature WLST and inappropriate reassurance.

 

🦪  OYSTERS — HIDDEN GEMS

Oyster 1: The 'self-fulfilling prophecy' bias is real and kills salvageable patients.

Studies from the TTM trial era demonstrate that early withdrawal of life-sustaining treatment (WLST) — before multimodal assessment — accounts for a substantial proportion of ICU deaths after cardiac arrest. When clinicians prognosticate early and communicate pessimism, families consent to WLST, making the prognosis appear correct. The antidote is a structured, timed, multidisciplinary prognostication protocol that defers WLST decisions.

Oyster 2: NSE is powerful — but laboratory variation destroys its utility.

Neuron-specific enolase (NSE) is the most validated serum biomarker post-arrest. A value >60 µg/L at 48–72 h has high specificity for poor prognosis. However, haemolysis (from red cell lysis) raises NSE by up to 40 µg/L. Always request a concurrent haemolysis index. An NSE result without haemolysis correction is diagnostically worthless.

Oyster 3: A normal EEG on day 1 is not reassuring in the way most clinicians think.

Continuous EEG monitoring in the first 24 hours primarily serves to detect non-convulsive seizures — a treatable secondary injury — rather than to confirm good prognosis. An EEG that is normal at 12 hours may show malignant patterns at 36 hours as sedation clears. A single snapshot EEG is insufficient; 24-hour continuous monitoring is the standard of care in comatose post-arrest patients.

 

⚡  CLINICAL HACKS & TIPS

Hack 1: Use the '3-3-3 rule' for prognostication timing.

Prognosticate no earlier than: 3 days after ROSC, and at least 3 days after TTM ends, using at least 3 independent modalities. This triple-three heuristic encodes the ERC 2021 guidelines into a bedside memory aid.

Hack 2: The 'traffic light' framework for bedside communication.

Use a three-tier verbal framing with families: RED = multiple poor prognostic signs consistently pointing to severe injury; AMBER = mixed signals, uncertainty is honest; GREEN = reassuring signs emerging. This prevents binary thinking (will he live or die?) and aligns families with the temporal reality of neurological recovery.

Hack 3: Quantitative pupillometry — the NPi threshold to remember.

A Neurological Pupil index (NPi) <2 bilaterally at 72 h has specificity approaching 100% for CPC 4–5 outcome. If your unit has a pupillometer (and it should), document NPi serially from day 1. An NPi that falls from 3 to <2 over 24 hours is a clinically significant deterioration signal.

 

🔬  STATE-OF-THE-ART UPDATES

Update 1: TTM2 trial — the death of '33 is better than 36'.

The landmark TTM2 trial (Dankiewicz et al., NEJM 2021, n=1900) demonstrated no difference in all-cause mortality between TTM at 33°C versus normothermia (targeted at ≤37.8°C). This overturned a decade of 33°C dogma. The take-home: fever prevention (>37.7°C strictly avoided) remains essential; active cooling to 33°C is no longer mandated but remains an option.

Update 2: EEG standardisation — the ACNS terminology revolution.

The American Clinical Neurophysiology Society (ACNS) standardised critical care EEG terminology has transformed post-arrest EEG interpretation. 'Malignant' EEG patterns — suppression, burst-suppression, isoelectric trace, or absence of EEG reactivity — are now reproducible descriptors with validated prognostic weight. Training in this terminology is no longer optional for intensivists managing cardiac arrest survivors.

Update 3: GFAP and NfL — the next-generation biomarkers.

Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are emerging as superior biomarkers to NSE. NfL in particular shows excellent discrimination for poor neurological outcome at 48–72 h and is unaffected by haemolysis. While not yet in routine clinical use, expect these to enter guidelines within 2–3 years.

 

Diagnostic Nuances: Separating Good from Great Clinicians

The multimodal prognostication algorithm recommended by the ERC 2021 guidelines stratifies assessment into four complementary domains:

1. Clinical neurological examination: At ≥72 h post-ROSC (after sedation washout confirmed by pharmacokinetic assessment), evaluate: (a) PLR — bilaterally absent is a 'major' predictor; (b) corneal reflex — bilaterally absent; (c) motor response — ≤2 alone is insufficient but contributes to the constellation. Crucially, document the timing of last sedative/paralytic dose and calculate expected clearance. A pragmatic bedside test: can the patient follow commands to 'open eyes' or 'squeeze my hand'? Consistent command-following is a favourable sign even without full consciousness.

2. Electrophysiology — SSEP: Bilateral absence of the N20 cortical response on short-latency somatosensory evoked potentials (SSEPs) is the single most specific prognostic test available (specificity ~100%, FPR <1% with TTM-corrected interpretation). However, sensitivity is only ~45%, meaning a present N20 does not guarantee good outcome. SSEPs should ideally be performed at ≥24 h after normothermia restoration.

3. Neuroimaging — CT and MRI: Non-contrast CT within 24–48 h assesses grey-white matter ratio (GWR). A GWR <1.2 in the basal ganglia region predicts poor prognosis with high specificity. Brain MRI at 2–5 days using DWI/ADC mapping is more sensitive: diffuse cortical or deep grey matter restriction indicates severe hypoxic injury. An important pitfall: a normal early CT does not exclude significant injury — MRI is the definitive imaging modality.

4. Biomarkers — NSE and emerging tests: NSE at 48 h >33 µg/L (moderate concern) and >60 µg/L (high specificity for poor outcome) should be interpreted with haemolysis index. Serial rising values are more concerning than a single elevated reading. GFAP and NfL are promising adjuncts where available.

 

The Prognostication Algorithm at a Glance

Step 1: Confirm adequate observation period (≥72 h post-ROSC, ≥72 h post-TTM end). Step 2: Exclude confounders (residual sedation, metabolic encephalopathy, haemodynamic instability). Step 3: Apply clinical examination. Step 4: Obtain EEG (continuous 24 h) and SSEP. Step 5: Request neuroimaging (CT or MRI). Step 6: Measure NSE at 48 and 72 h. Step 7: Synthesise findings across modalities. Step 8: Convene multidisciplinary family meeting with palliative care input.

 

Management Intricacies: Drugs, Doses, and Pitfalls

Temperature management: Target 32–36°C for 24 hours, then controlled rewarming at 0.25–0.5°C per hour to 37°C. Following TTM2, normothermia protocols target ≤37.7°C using active cooling for a minimum of 72 h post-ROSC. Avoid fever aggressively — even a single hour of temperature >38°C has been associated with worsened neurological outcomes in observational data.

Sedation and analgesia: During TTM, use short-acting agents: propofol and remifentanil or fentanyl are preferred for their rapid offset. Avoid benzodiazepines where possible — their prolonged effect confounds neurological assessment. Conduct daily sedation holds with clinical reassessment once normothermia is established.

Seizure management: Continuous EEG should guide treatment. Non-convulsive status epilepticus (NCSE) occurs in up to 30% of comatose survivors. Treat with IV levetiracetam (loading dose 60 mg/kg, max 4,500 mg) as first-line, followed by valproate or lacosamide. Prophylactic anticonvulsants are not routinely recommended. Distinguish NCSE from myoclonic status (which is often refractory and carries a poor prognosis regardless of treatment).

Haemodynamic targets: Target MAP ≥65–70 mmHg; avoid hypotension (MAP <65 mmHg) scrupulously. Some centres target MAP 80–100 mmHg for the first 24 h based on cerebrovascular autoregulation loss post-arrest. SpO2 94–98%; PaCO2 35–45 mmHg (avoid hypocapnia — cerebral vasoconstriction worsens ischaemia). Hyperoxia (PaO2 >300 mmHg) should be avoided.

 

🚨  WHEN TO ESCALATE / WHEN TO WATCH

Escalate to neurology/neurocritical care immediately if:

• Continuous EEG shows NCSE or malignant patterns requiring expert interpretation

• Bilateral absent N20 on SSEP — requires specialist confirmation before any WLST discussion

• Refractory myoclonic status epilepticus

• Family requesting second opinion on prognosis

Watch and wait (do NOT prognosticate early) if:

• Sedation/paralytic clearance not confirmed pharmacokinetically

• Metabolic derangement present (uraemia, hyponatraemia, hepatic failure)

• Only 48 h has elapsed since ROSC — even with apparently catastrophic signs, wait

• Mixed prognostic signals (e.g., absent PLR but present N20 — these are conflicting and demand reassessment)

• Signs of neurological improvement emerging (spontaneous eye opening, tracking, purposeful movement)

 

Summary: Multimodal Prognostication at a Glance

Domain	Key Points
TTM	Target 32–36 °C for 24 h; avoid fever (>37.7 °C) for ≥72 h post-arrest
Earliest safe prognostication	≥72 h after ROSC (or ≥72 h after TTM ends)
Pupillary reflexes	Bilateral absence = poor prognosis (Se 20%, Sp ~100%)
SSEP N20	Bilateral absence = poor prognosis (Sp ~100% when TTM-corrected)
EEG	Burst suppression / malignant patterns at 24 h → poor prognosis
NSE	>60 µg/L at 48–72 h → poor prognosis (use with other modalities)
CT/MRI Brain	GWR <1.2 (CT) or DWI restriction (MRI) → poor prognosis
Clinical signs to avoid	Motor response alone (confounded by TTM and sedation)
Self-fulfilling prophecy	Avoid early WLST before multimodal assessment
Family communication	Use 'waiting for certainty' framing; avoid premature prognostication

 

Mnemonic: PROGNOSE

●       P — Pupils (bilaterally absent PLR = strong poor predictor)

●       R — Reflex (corneal, oculocephalic — absent bilaterally adds weight)

●       O — Only after 72 hours (never prognosticate early)

●       G — GFAP/NSE (biomarkers with haemolysis correction)

●       N — Neuroimaging (CT GWR <1.2; MRI DWI restriction)

●       O — Only multimodal (no single test decides)

●       S — SSEP (absent N20 = most specific poor predictor)

●       E — EEG (malignant patterns, absence of reactivity)

 

References

1. Nolan JP, Sandroni C, Böttiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Intensive Care Med. 2021;47(4):369–421.

2. Sandroni C, D'Arrigo S, Callaway CW, et al. The rate of brain death and organ donation in patients resuscitated from cardiac arrest: a systematic review and meta-analysis. Intensive Care Med. 2016;42(6):942–51.

3. Westhall E, Rossetti AO, van Rootselaar AF, et al. Standardized EEG interpretation accurately predicts prognosis after cardiac arrest. Neurology. 2016;86(16):1482–90.

4. Oddo M, Sandroni C, Citerio G, et al. Quantitative versus standard pupillary light reflex for early prognostication in comatose cardiac arrest patients: an international prospective multicenter double-blind study. Intensive Care Med. 2018;44(12):2102–11.

5. Dragancea I, Rundgren M, Englund E, Friberg H, Cronberg T. The influence of induced hypothermia and delayed prognostication on the mode of death after cardiac arrest. Resuscitation. 2013;84(3):337–42.

6. Moseby-Knappe M, Mattsson-Carlgren N, Stammet P, et al. Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Med. 2021;47(6):984–94.

7. Callaway CW, Donnino MW, Fink EL, et al. Part 8: post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2):S465–82.

8. Rossetti AO, Tovar Quiroga DF, Juan E, et al. Electroencephalography predicts poor and good outcomes after cardiac arrest: a two-center study. Crit Care Med. 2017;45(7):e674–82.

9. Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013;369(23):2197–206.

10. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384(24):2283–94.

11. Sandroni C, Cariou A, Cavallaro F, et al. Prognostication in comatose survivors of cardiac arrest: an advisory statement from the European Resuscitation Council and the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1816–31.

12. Bongiovanni F, Romagnosi F, Barbella G, et al. Standardized EEG analysis to reduce the uncertainty of outcome prognostication after cardiac arrest. Intensive Care Med. 2020;46(5):963–72.

13. Tsetsou S, Novy J, Oddo M, Rossetti AO. Multimodal outcome prognostication after cardiac arrest and targeted temperature management: analysis at 36°C. Neurocrit Care. 2018;28(1):104–9.

14. Sandroni C, D'Arrigo S, Cacciola S, et al. Prediction of good neurological outcome in comatose survivors of cardiac arrest: a systematic review. Intensive Care Med. 2022;48(4):389–413.

15. Cronberg T, Brizzi M, Liedholm LJ, et al. Neurological prognostication after cardiac arrest — recommendations from the Swedish Resuscitation Council. Resuscitation. 2013;84(7):867–72.

ICP AND CPP MONITORING IN THE ICU

REVIEW ARTICLE  |  NEUROCRITICAL CARE  |  INTERNAL MEDICINE

ICP AND CPP MONITORING IN THE ICU

A Clinician's Masterclass

DR Neeraj Manikath , claude.ai

Targeted at Postgraduate Trainees, Residents, and Practicing Consultants in Internal Medicine & Critical Care

 

The Case That Changed My Practice

📋 CLINICAL VIGNETTE

A 34-year-old construction worker arrived in the emergency department following a fall from scaffolding. GCS on arrival: 9 (E2V3M4). CT head revealed a right-sided acute subdural haematoma with 7 mm midline shift and effacement of the basal cisterns. He was intubated. Blood pressure: 160/90 mmHg. MAP: 105 mmHg — "a good pressure," the nurse remarked.

What no one had accounted for: his post-operative ICP was running at 28 mmHg. CPP = 105 − 28 = 77 mmHg — marginally adequate. Over the next six hours, nursing interventions caused transient MAP dips to 80 mmHg. CPP fell to 52 mmHg. He developed bilateral extensor posturing and died on day four.

He did not die from his primary injury alone. He died from preventable secondary brain injury — the silent killer of neurotrauma. At the heart of preventing it lies the discipline of ICP and CPP monitoring.

 

1. Scope of the Problem

Traumatic brain injury (TBI) affects an estimated 69 million individuals globally each year. Severe TBI (GCS ≤ 8) carries a mortality of 30–40%, with up to 50% of survivors sustaining significant neurological disability. Intracranial hypertension — defined as sustained ICP > 22 mmHg — occurs in 40–70% of patients with severe TBI and is one of the strongest independent predictors of poor neurological outcome.

Beyond trauma, ICP elevation threatens survival across a broad neurocritical care spectrum: aneurysmal subarachnoid haemorrhage (SAH), spontaneous intracerebral haemorrhage (ICH), large-hemispheric ischaemic stroke, fulminant hepatic failure, hypertensive encephalopathy, and meningitis/encephalitis. ICP and CPP monitoring is not a subspecialty luxury — it is core critical care competency.

 

2. Pathophysiology — The Clinically Relevant Essentials

The Monro-Kellie Doctrine: Still Alive and Kicking

The skull is a rigid box containing brain parenchyma (~80%), CSF (~10%), and blood (~10%) — a fixed total volume. Any increase in one component must be compensated by a reciprocal reduction in another. When compensatory mechanisms are exhausted, even a small volume increment causes an exponential rise in ICP.

💡 Key Teaching Point: The ICP-volume curve is not linear. The brain's compliance reserve is finite. A brain at the steep portion of this curve is at imminent risk — a 1 mL CSF bolus challenge via EVD can identify this within seconds.

Cerebral Perfusion Pressure: The Upstream Determinant

CPP = MAP − ICP  |  Normal CPP: 60–70 mmHg. Below 50 mmHg, CBF falls precipitously. Above 70 mmHg, hyperaemia and vasogenic oedema may worsen outcomes in certain injury subtypes.

Cerebral Autoregulation: The Concept Clinicians Underuse

In a healthy brain, CBF remains constant across a MAP range of 60–160 mmHg. In injured brains, autoregulation is frequently impaired — the brain becomes pressure-passive, with CBF rising and falling directly with MAP. The Optimal CPP (CPPopt) — the CPP at which autoregulation is most intact — can now be estimated from continuous ICP/MAP monitoring.

 

3. Indications for ICP Monitoring

Brain Trauma Foundation (BTF) Guidelines (4th Edition, 2016) recommend ICP monitoring in:

•        Severe TBI (GCS ≤ 8) with abnormal CT (haematoma, contusion, oedema, herniation, or compressed basal cisterns)

•        Severe TBI with normal CT + two or more of: age > 40, motor posturing, SBP < 90 mmHg

Emerging indications: Large hemispheric ischaemic stroke with malignant oedema; Spontaneous ICH with impaired consciousness; Fulminant hepatic failure; Refractory bacterial meningitis/encephalitis with coma.

 

4. Modalities of ICP Monitoring

The Gold Standard: External Ventricular Drain (EVD)

Placed in the frontal horn via a burr hole (Kocher's point: 1 cm anterior to the coronal suture, 2.5–3 cm from midline). Advantages: measures and treats simultaneously (CSF drainage lowers ICP in real time), allows CSF sampling, recalibrateable, cost-effective. Infection risk: 5–14%; haemorrhage risk: ~1–2%.

Parenchymal Monitors (Licox, Codman, Camino)

Placed into brain parenchyma via a frontal bolt. Accurate, lower infection risk, but cannot drain CSF and cannot be recalibrated (zero drift is a recognised limitation).

 

Feature	EVD	Parenchymal Monitor
CSF Drainage	✓ Yes	✗ No
Recalibration	✓ Yes	✗ No
Infection Risk	Higher (5–14%)	Lower
Accuracy	Gold Standard	Very Good
Placement Complexity	Higher	Lower

 

Emerging Non-Invasive Monitoring

•        ONSD ultrasonography: Optic nerve sheath diameter > 5.7 mm correlates with ICP > 20 mmHg. Portable, risk-free. Best as a screening tool.

•        Pupillometry (NPi): Automated infrared detection of herniation; NPi < 3.0 warrants urgent re-evaluation.

•        Transcranial Doppler (TCD): Pulsatility index > 1.4 is a surrogate of elevated ICP.

•        NIRS: Regional cerebral oxygen saturation; adjunct, not replacement.

 

5. 🪙 Clinical Pearls

🪙 Pearl 1 — The ICP Waveform Is a Diagnostic Tool in Itself

Normal ICP waveform: P1 (percussion — arterial pulsation), P2 (tidal — brain compliance), P3 (dicrotic — aortic valve closure). When P2 > P1, compliance is impaired — the brain is on the steep part of its pressure-volume curve. Act before the number crosses 20 mmHg.

 

🪙 Pearl 2 — Normal ICP Does Not Equal Normal Brain

Plateau waves (Lundberg A waves): sustained ICP spikes to 50–100 mmHg for 5–20 minutes represent episodic ischaemia. A single A wave, even if ICP normalises spontaneously, warrants immediate escalation of treatment.

 

🪙 Pearl 3 — CPP Is Not Everything

A CPP of 65 mmHg means very different things with intact vs. abolished autoregulation. In the latter, higher CPP may drive more oedema. Use the Pressure Reactivity Index (PRx — correlation between ICP and MAP): PRx > +0.3 signals impaired autoregulation.

 

🪙 Pearl 4 — Bilateral ICP Monitoring Changes Management

Midline shift does not guarantee the contralateral hemisphere is at lower pressure. In bifrontal contusions or bilateral pathology, unilateral ICP monitoring may miss a clinically critical pressure gradient.

 

 

6. 🦪 Oysters — Hidden Gems Most Clinicians Miss

🦪 Oyster 1 — The 'Talk and Die' Patient Has Elevated ICP, Not Just a Bleed

The classic lucid interval in extradural haematoma reflects the time for haematoma expansion to exhaust intracranial compliance. This is a textbook ICP physiology lesson at the bedside.

 

🦪 Oyster 2 — Hyperventilation Is a Bridge, Not a Treatment

Acute hyperventilation (PaCO₂ 30–35 mmHg) reduces ICP via cerebral vasoconstriction but causes ischaemia if sustained. Use only as a bridge to definitive treatment. Target PaCO₂ 35–40 mmHg routinely; < 35 only for impending herniation.

 

🦪 Oyster 3 — Sodium and ICP: The Gradient Matters, Not Just the Number

Mannitol needs an osmotic gradient across the BBB. If the patient is already hypertonic (Na > 155), its effect is blunted. Target serum osmolality 300–320 mOsm/kg with sodium 145–155 mEq/L.

 

🦪 Oyster 4 — The Cushing Reflex Is a Pre-terminal Sign

Hypertension + bradycardia + irregular breathing = brainstem compression. By the time you recognise this triad, you are minutes from irreversible injury. This demands immediate ICP-lowering measures and neurosurgical escalation — NOT observation.

 

 

7. ⚡ Clinical Hacks and Tips

⚡ Hack 1 — The '30-30-30' Rule

Head of bed at 30°, MAP ≥ 70 mmHg, ICP ≤ 20 mmHg. Three default parameters for TBI management. Simple, memorable, actionable. Each degree of head elevation beyond neutral reduces ICP by ~1 mmHg up to 30°.

 

⚡ Hack 2 — Use the EVD to Test Compliance

Withdraw 3–5 mL of CSF and observe the ICP response. A drop > 5 mmHg per mL suggests reasonable compliance reserve. Minimal response signals maximum compliance consumption — danger zone.

 

⚡ Hack 3 — Propofol's Dirty Secret

Propofol infusion syndrome (PRIS) — metabolic acidosis, rhabdomyolysis, renal failure, arrhythmias — is a real risk at > 4–5 mg/kg/hr for > 48 hours. Monitor CK daily at high doses; switch to midazolam or ketamine if needed.

 

⚡ Hack 4 — Ketamine: Rehabilitating a Maligned Drug

The old contraindication to ketamine in TBI was from spontaneously breathing patients. In intubated, ventilated patients, multiple trials show ketamine does NOT raise ICP and may be neuroprotective. Excellent for ICP-spiking events: suctioning, repositioning.

 

⚡ Hack 5 — The Pupil Asymmetry Trick

Anisocoria > 1 mm in a comatose patient = ICP emergency until proven otherwise. Measure NPi with pupillometry if available. Act first, scan second.

 

 

8. State-of-the-Art Updates

BEST-TRIP Trial (NEJM, 2012) — Still Misinterpreted

This landmark trial found no difference in 6-month outcomes between ICP-monitor-guided and imaging-guided therapy. Many used this to abandon monitoring. The correct interpretation: monitoring alone does not save lives — it is what you do with the data that matters. In resource-rich settings with experienced neurocritical care teams, ICP monitoring remains standard of care.

CPPopt — Individualised CPP Targets

CPPopt — derived from continuous correlation of CPP with PRx — is moving from research to bedside reality. The COGiTATE trial (2020) demonstrated feasibility in clinical practice. CPP targets should be individualised, not uniform — the era of 'one CPP fits all' is over.

Decompressive Craniectomy — DECRA and RESCUEicp Clarified

•        DECRA (NEJM 2011): Bifrontal decompressive craniectomy reduced ICP but worsened unfavourable outcomes — de-emphasising prophylactic craniectomy.

•        RESCUEicp (NEJM 2016): In truly refractory ICP (> 25 mmHg despite maximal therapy), craniectomy reduced mortality but increased severe disability survivors. Key lesson: craniectomy saves life but may not preserve function — this must inform goals-of-care discussions.

Brain Oxygenation Monitoring: PbtO₂

Normal PbtO₂: 20–35 mmHg. PbtO₂ < 20 mmHg = ischaemia; < 10 mmHg = critical. The BOOST-3 trial examines whether PbtO₂-directed therapy added to ICP monitoring improves outcomes in severe TBI. Preliminary data suggest benefit, particularly in reducing radiological injury progression.

Fourth-Tier Therapy: Moderate Hypothermia

Cooling to 32–34°C reduces ICP by 10–15 mmHg. However, POLAR-RCT (NEJM 2018) showed no outcome benefit with prophylactic hypothermia in TBI. It remains a rescue option for refractory ICP — not a first-line strategy.

 

9. Diagnostic Nuances

History

•        Time of peak consciousness after injury (lucid interval → extradural > subdural haematoma)

•        Anticoagulation/antiplatelet use — expanded haematoma risk

•        Prior cranial surgery (burr holes, shunts) — altered baseline compliance

Examination — The 90-Second ICP Assessment

•        GCS trajectory: Worsening = alarm. Trend > number.

•        Pupils: Size, reactivity, symmetry. Anisocoria > 1 mm in a comatose patient = emergency.

•        Fundoscopy: Papilloedema (subacute marker); retinal venous pulsations present = ICP likely < 20 mmHg.

•        Cushing's triad: Hypertension + bradycardia + irregular breathing = brainstem compression.

•        Respiratory pattern: Cheyne-Stokes = bilateral hemispheres; central hyperventilation = midbrain; ataxic = medullary.

Investigations

•        CT head: Absent cisterns, midline shift > 5 mm, bilateral injury, subarachnoid blood predict severe intracranial hypertension.

•        MRI (FLAIR/DWI): Identifies diffuse axonal injury (DAI) missed by CT; prognostic, not acute management.

•        Serum GFAP and UCH-L1: FDA-cleared biomarkers predicting CT positivity — may help triage in resource-limited settings.

 

10. Management Intricacies: The Tiered Approach

Tier 0 — Universal Measures (All Patients)

•        Head of bed 30°, neutral neck position

•        Normothermia — fever raises ICP ~1 mmHg per °C

•        Normoglycaemia (avoid hypoglycaemia and hyperglycaemia equally)

•        Mild hypernatraemia: Na 145–155 mEq/L

•        PaCO₂ 35–40 mmHg; PaO₂ > 80 mmHg

Tier 1 — First-Line ICP Treatment (ICP > 22 mmHg)

•        CSF drainage via EVD: Drain 5–10 mL aliquots; reassess after each

•        Sedation and analgesia: Propofol 1–4 mg/kg/hr + opioid infusion. Daily sedation holds UNLESS ICP-unstable.

•        Mannitol 20%: 0.25–1.5 g/kg IV over 15–20 min. Serum osmolality ceiling: 320 mOsm/kg.

•        Hypertonic saline (3% or 23.4%): Preferred in hypovolaemia or liver failure (avoids osmotic diuresis). 23.4% NaCl 30 mL bolus (central line) for acute herniation — faster and more sustained than mannitol in comparative studies.

Tier 2 — Escalation

•        Neuromuscular blockade: Eliminates ventilator dyssynchrony and shivering

•        Barbiturate coma: High-dose pentobarbital/thiopentone — profound CMRO₂ reduction. Continuous EEG mandatory for burst suppression titration. Significant hypotension risk.

•        Moderate hypothermia (32–34°C): Rescue only, not prophylaxis

Tier 3 — Surgical

•        Haematoma evacuation: Extradural, subdural, ICH with mass effect

•        Decompressive craniectomy: Reserved for ICP > 25 mmHg refractory to all medical therapy, with full goals-of-care discussion

 

Drug	Critical Pitfall
Mannitol	Contraindicated if osmolality > 320; paradoxical oedema if BBB breached
Propofol	PRIS at > 4 mg/kg/hr for > 48 hrs; monitor CK daily
Dexamethasone	NO role in TBI or haemorrhage; indicated only for vasogenic oedema (tumour, abscess)
Nimodipine	For vasospasm in SAH only — NOT a generalised ICP drug
Hypertonic saline > 3%	Central line mandatory; peripheral administration causes phlebitis

 

 

11. When to Escalate / When to Watch

🚨 ESCALATE IMMEDIATELY IF:

• ICP sustained > 22 mmHg for > 5 minutes despite head repositioning

• CPP < 60 mmHg despite adequate MAP

• Lundberg A waves (plateau waves) on ICP trace

• New pupillary asymmetry (anisocoria > 1 mm in a comatose patient)

• Cushing's triad: hypertension + bradycardia + irregular breathing

• NPi < 3.0 on automated pupillometry

• GCS drop ≥ 2 points on serial assessment

 

✅ SAFE TO WATCH (with close monitoring) IF:

• ICP 18–22 mmHg with clear, resolving precipitant (fever, coughing, suctioning)

• Stable CPP > 65 mmHg with normal waveform morphology (P1 > P2)

• B-waves only (oscillating ICP 0.5–2 Hz, amplitude < 20 mmHg — vasomotor cycling, not crisis)

• Pupil responses intact, GCS stable, trends improving

 

12. The BRAIN Mnemonic — A Memorable Summary

 

Letter	Principle
B — Baseline matters	Know the TREND, not just the number. A rising ICP from 12 to 20 mmHg is more alarming than a stable 22 mmHg.
R — Reflex responses	ICP spikes to suctioning/turning are expected. Sustained elevation after withdrawal of the stimulus is the danger sign.
A — Autoregulation	Use PRx if available. If not, observe CPP response to MAP manoeuvres. The pressure-passive brain is vulnerable.
I — Individualise CPP	60–70 mmHg is the range. The specific patient may need CPPopt-guided fine-tuning. One size does not fit all.
N — Never treat the monitor alone	Treat the PATIENT. Clinical correlation is always paramount. Technology guides; the clinician decides.

 

13. At-a-Glance Quick Reference Table

 

Parameter	Normal	Treat at	Target
ICP	< 10 mmHg	> 22 mmHg	< 20 mmHg
CPP	60–70 mmHg	< 60 mmHg	60–70 mmHg (individualised)
PbtO₂	20–35 mmHg	< 20 mmHg	> 20 mmHg
PRx	< 0 (intact autoregulation)	> +0.3	Minimise toward 0
ONSD	< 5.0 mm	> 5.7 mm	< 5.0 mm
NPi	≥ 3.0	< 3.0	≥ 3.0
Serum osmolality	285–295 mOsm/kg	—	300–320 with osmotherapy
Serum sodium	136–145 mEq/L	—	145–155 (neuroprotection)

 

References

1. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6–15.

2. Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367(26):2471–2481.

3. Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med. 2011;364(16):1493–1502.

4. Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med. 2016;375(12):1119–1130.

5. Aries MJ, Czosnyka M, Budohoski KP, et al. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. Crit Care Med. 2012;40(8):2456–2463.

6. Stocchetti N, Carbonara M, Citerio G, et al. Severe traumatic brain injury: targeted strategies and new European guidelines. Lancet Neurol. 2017;16(6):452–464.

7. Rosenfeld JV, Maas AI, Bragge P, et al. Early management of severe traumatic brain injury. Lancet. 2012;380(9847):1088–1098.

8. Helbok R, Olson DM, Le Roux PD, Vespa P. Intracranial pressure and cerebral perfusion pressure monitoring in non-TBI patients. Neurocrit Care. 2014;21(Suppl 2):S85–94.

9. Oddo M, Bösel J. Monitoring of brain and systemic oxygenation in neurocritical care patients. Neurocrit Care. 2014;21(Suppl 2):S103–120.

10. Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for intracranial hypertension after traumatic brain injury. N Engl J Med. 2015;373(25):2403–2412.

11. Kirkman MA, Smith M. Intracranial pressure monitoring, cerebral perfusion pressure estimation, and ICP/CPP-guided therapy. Br J Anaesth. 2014;112(1):35–46.

12. Robba C, Cardim D, Tajsic T, et al. Ultrasound non-invasive measurement of intracranial pressure in neurointensive care. PLoS Med. 2017;14(7):e1002356.

13. Le Roux P, Menon DK, Citerio G, et al. Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care. Neurocrit Care. 2014;21(Suppl 2):S1–26.

14. Gritti P, Lorini FL, Lanterna LA, et al. Application of advanced neuromonitoring in the management of severe traumatic brain injury. J Neurosurg Sci. 2018;62(5):556–565.

15. Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16(9):721–729.

 

Conflict of interest: None declared  |  Funding: None  |  Word count: ~2,400